Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 301

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Fibroblast Growth Factor 21 as an emerging metabolic regulator: clinical perspectives

Open access
Woo, Y. C., Xu, Aimin, Wang, Yu, Lam, Karen S. L.·2013·Clinical Endocrinology

Abstract

Summary: Fibroblast growth factor 21 (FGF 21), a metabolic hormone predominantly produced by the liver, is also expressed in adipocytes and the pancreas. It regulates glucose and lipid metabolism through pleiotropic actions in these tissues and the brain. In mice, fasting leads to increased PPAR‐α mediated expression of FGF 21 in the liver where it stimulates gluconeogenesis, fatty acid oxidation, and ketogenesis, as an adaptive response to fasting and starvation. In the fed state, FGF 21 acts as an autocrine factor in adipocytes, regulating the activity of PPAR‐γ through a feed‐forward loop mechanism. Administration of recombinant FGF 21 has been shown to confer multiple metabolic benefits on insulin sensitivity, blood glucose, lipid profile and body weight in obese mice and diabetic monkeys, without mitogenic or other side effects. Such findings highlight the potential role of FGF 21 as a therapeutic agent for obesity‐related medical conditions. However, in human studies, high circulating FGF 21 levels are found in obesity and its related cardiometabolic disorders including the metabolic syndrome, type 2 diabetes, non‐alcoholic fatty liver disease and coronary artery disease. These findings may indicate the presence of FGF 21 resistance or compensatory responses to the underlying metabolic stress, and imply the need for supraphysiological doses of FGF 21 to achieve therapeutic efficacy. On the other hand, serum FGF 21 has been implicated as a potential biomarker for the early detection of these cardiometabolic disorders. This review summarizes recent developments in the understanding of FGF 21, from physiological and clinical perspectives.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cen.12095

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Cited by

See all 301

Metadata

Authors
Woo, Y. C., Xu, A., Wang, Y., & Lam, K. S. L.
Venue
Clinical Endocrinology
Publisher
Wiley
Published
2013-03-12
Volume
78
Issue
4
Pages
489-496
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
OpenAlex
W2085379045
Cited by
301
References
56
FWCI
7.43
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fibroblast Growth Factor 21 as an emerging metabolic regulator: clinical perspectives. https://app.cochat.ai/papers/10.1111/cen.12095
The paper
Woo, Y. C., Xu, A., Wang, Y., & Lam, K. S. L. (2013). Fibroblast Growth Factor 21 as an emerging metabolic regulator: clinical perspectives. Clinical Endocrinology. https://doi.org/10.1111/cen.12095

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.